Wolfe Laboratories, Inc. is a leading translational drug development contract research organization (CRO), bridging discovery through early clinical studies in the pharmaceutical sciences. Clients have relied on the company since 1999 for ongoing functional support as well as for discrete projects that integrate Wolfe Laboratories’ drug development functions, which include analytical, preformulation, DMPK, formulation and process development, and GLP/GMP testing.
Translational development provides significant financial and strategic benefits to drug development companies, offering the potential to accelerate programs and increase the probability of achieving key milestones. This in turn increases the commercial value of these programs while also addressing important areas of human health by supporting the conversion of innovative early-stage projects to much-needed therapies.
Wolfe’s translational development capabilities and its geographic location allow the company to meet the needs of its diverse market segments, including small-, mid- and large-size pharmaceutical and biotechnology companies, academics drug discovery groups and the NIH. Wolfe is a unique CRO in that the company thrives on being a true partner to its clients, engaging in mutual problem solving and providing a high level of customization to adapt to a project’s unique needs. Clients appreciate Wolfe’s high-quality work, speed, flexibility and creativity. Wolfe Laboratories is recognized as a highly skilled and customer-friendly organization that integrates numerous scientific disciplines and applies that knowledge and experience to yield productive early drug development services. Wolfe Laboratories’ ability to develop technically challenging molecules and rapidly advance them to proof-of-concept studies makes the company an attractive strategic partner.